Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.47 | N/A | -85.37% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.47 | N/A | -85.37% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about recent performance but maintained a focus on future opportunities. They did not provide specific guidance for the upcoming quarters.
Management acknowledged challenges in meeting financial expectations.
They emphasized a focus on long-term growth despite current setbacks.
Twist Bioscience's disappointing earnings report, particularly the significant EPS miss, led to a sharp decline in the stock price by 19%. Investors may be concerned about the company's ability to meet financial expectations in the near term. The lack of revenue data and guidance adds to the uncertainty surrounding the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ARCHER-DANIELS MIDLA
Jul 30, 2024